Doctor of Podiatric Medicine Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Edward Lang

Podiatrist New Orleans, LA Doctor of Podiatric Medicine

NPI 1699798769 CMS profile 76569

2626 Jena Street, New Orleans, LA 70115

Open in the dashboard

General payments

$7,255

140 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Edward Lang of New Orleans, LA is reported in the CMS Open Payments database as having received $7,255 across 140 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 88th percentile of Podiatrist profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $2,017 13
2024 General $1,255 6
2023 General $76 1
2022 General $1,898 7
2021 General $219 6
2020 General $1,122 51
2019 General $669 56

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Edward Lang
  • Podiatrist median
  • Middle half of Podiatrist
  • National median

In program year 2025, general payments to Edward Lang were reported at $2,017. Among 4,572 Podiatrist profiles paid that year, the median was $260 and the middle half received between $94 and $777.

Show as a table
Year Edward Lang Podiatrist median Middle half National median
2019 $669 $196 $72–$601 $163
2020 $1,122 $118 $38–$335 $114
2021 $219 $169 $57–$573 $132
2022 $1,898 $220 $74–$782 $149
2023 $76 $208 $71–$635 $160
2024 $1,255 $237 $87–$681 $164
2025 $2,017 $260 $94–$777 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Treace Medical Concepts, Inc. $3,879 17 payments
  2. Alon Medical Technology $901 3 payments
  3. Ortho Dermatologics, a division of Bausch Health US, LLC $832 26 payments
  4. Arthrex, Inc. $406 6 payments
  5. Stryker Corporation $349 13 payments
  6. Zyla Life Sciences $226 32 payments
  7. Zimmer Biomet Holdings, Inc. $196 5 payments
  8. ASSERTIO THERAPEUTICS, Inc. $162 19 payments
  9. Horizon Therapeutics plc $135 12 payments
  10. BioPoly LLC $76 1 payment
  11. Other $92 6 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Travel and Lodging $4,460 10 payments
  2. Food and Beverage $2,106 127 payments
  3. Consulting Fee $680 1 payment
  4. Education $8 2 payments
Products named General payments · program years 2019–2025
  1. LAPIPLASTY SYSTEM $2,845 11 payments
  2. JUBLIA $832 26 payments
  3. LAPIPLASTY $798 1 payment
  4. ANCHORAGE $220 10 payments
  5. SPRIX $151 22 payments
  6. ZIPSOR $145 18 payments
  7. BRYHALI $118 19 payments
  8. Foot & Ankle-None $95 1 payment
  9. ZORVOLEX $75 10 payments
  10. VIMOVO $55 4 payments
  11. Other $557 36 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 12 drugs

Part D claims

527

Median for Podiatry: 160

Drug cost

$8,650

Median for Podiatry: $2,368

Branded share of claims

28.7%

Median for Podiatry: 12.7%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Ketoconazole Generic 120 $2,616
Ciclopirox Ciclopirox Olamine Brand 122 $2,340
Mupirocin Generic 57 $924
Ciclopirox Generic 20 $817
Cefdinir Generic 57 $540
Celecoxib Generic 24 $326
Clotrimazole-Betamethasone Clotrimazole/Betamethasone Dip Brand 14 $305
Doxycycline Hyclate Generic 17 $227
Methylprednisolone Generic 29 $209
Naproxen Generic 23 $149

The 10 drugs with the highest cost, of 12 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 14,093 Part D prescribers listed as Podiatry; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 39 billing codes

Paid by Medicare

$84,033

Medicare's payments for the services billed

Medicare patients

206

Average age 74

Services billed

1,460

118 women, 88 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 68%
Arthritis 52%
Diabetes 29%
Chronic kidney disease 20%
Cancer 20%
Ischemic heart disease 19%
Depression 18%
Osteoporosis 14%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

140 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record